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1. Introduction 
The liver is a unique organ that is rich in cellular effectors for diverse systems, including the 
innate immune system, which plays a central role in hepatocellular injury (Gabay & 
Kushner, 1999). The innate immune system is based on broadly specific antigen recognition 
and does not rely on the more specialized antigen recognition pathways of the adaptive 
immune system. Although the innate immune response has broad specificity and is 
complex, acute-phase proteins (APPs) have been identified as biomarkers of the innate 
response (Table 1). 
APPs are mostly synthesized in the liver. Their concentrations in plasma increase (positive 
APPs) or decrease (negative APPs) by at least 25% during inflammatory disorders. Most 
changes in APP concentration are due to infection, trauma, surgery, burns, tissue infarction, 
immunologically mediated or crystal-induced inflammation, and advanced cancer. Exercise, 
heatstroke, childbirth, or even psychological stress and some psychiatric disorders may also 
affect concentrations of these proteins. Cytokines are the chief stimulators and regulators of 
the production of these proteins. Interleukin (IL)-6 is the principal stimulator of APPs but 
other proinflammatory cytokines such as IL-1, tumor necrosis factor alpha (TNF-), 
interferon gamma (INF-), and transforming growth factor beta (TGF-), and chemokines 
such as IL-8 are also involved. 
In the liver, the Janus kinase signal transducer and activator of transcription (STAT) 
pathway has been implicated in the action of cytokines. STAT 1 and STAT 2, which are 
activated by INF-/, are involved in antiviral defense and the former is involved in liver 
inflammation and injury. STAT 3 has been implicated in the acute-phase response as well as 
in hepatoprotective effects and liver regeneration. This pathway is mostly activated by IL-6. 
STAT 4 and STAT 6 are associated with the ischemia/reperfusion cycle as promoters of and 
protectors against injury, respectively, and STAT 5 plays an important role in the regulation 
of hepatic genes and growth factors. Several studies have confirmed that IL-6 and IL-22 (a 
related cytokine) are responsible for important liver functions such as liver regeneration, 
glucose and lipid metabolism, and induction of antiapoptotic proteins (Gao, 2005). 
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ACUTE PHASE PROTEINS 
POSITIVE NEGATIVE 
Complement system Albumin 
C3, C4, C9, Factor B, C1 INH, C4b-binding protein, Mannose binding 
lectin 
Transferrin 
Coagulation and fibrinolytic system Transthyretin 
Fibrinogen, Plasminogen, Tissue plasminogen activator, Urokinase, 
Protein S, Vitronectin, Plasminogen activator inhibitor-1 
A2-HS 
glycoprotein 
Antiproteases Alpha-fetoprotein 
α1-Protease inhibitor, α1-Antichymotrypsin, Pancreatic secretory 
trypsin inhibitor, Inter- α -trypsin inhibitors 
Thyroxin-binding 
globulin 
Transport proteins Insulin-like 
growth factor-1 
Ceruloplasmin, Haptoglobin, Hemopexin Factor XII 
Inflammation responders Antithrombin 
Phospholipase A2, Lipopolysaccharide-binding protein, IL-1R 
antagonist, Granulocyte colony-stimulating factor 
Retinol-binding 
protein 
Others α1-Acid 
glycoprotein 
C-reactive protein, Serum amyloid A and P, Fibronectin, Ferritin, 
Angiotensinogen, α2-Macroglobulin 
 
Table 1. Descriptive table of some of the positive and negative acute-phase proteins. 
Many clinical applications are based on these proteins. The most widely used indicators of 
the APP response are erythrocyte sedimentation rate (ESR) and plasma C-reactive protein 
(CRP) concentration. The latter is considered more reliable because ESR changes slowly, 
whereas CRP concentration changes rapidly. 
2. Acute-phase proteins and the liver 
The synthesis of these proteins takes place, as mentioned before, in the liver, which is an 
organ with multiple implications for the metabolism of many compounds in the organism. It 
is logical to believe that any impairment in the functioning of this organ would affect the 
concentrations of and, therefore, the function of these proteins. In this chapter, the 
pathophysiology of these changes and the clinical repercussions thereof are discussed. 
To begin this chapter, it is important to review information on one of the APPs that has been 
most associated with the liver. It is well known that albumin is the most abundant protein in 
the body and albumin concentration is often used to assess liver function as well as the 
nutritional state of the patient because a decrease in the level of this protein is often associated 
with liver dysfunction. As such, it is an important component in several scales of dysfunction 
and prognosis. Albumin level is a component of the Child–Turcotte–Pugh scale, the Model of 
End-stage Liver Disease scale (specifically designed for the liver), and global scales such as the 
Sepsis-related Organ Failure scale and the Acute Physiology and Chronic Health Evaluation 
scale. Some authors (Chan, 2010) have detected albumin mRNA in the blood, indicating that 
cell death could occur in liver impairment, which would release this element to the blood. 
Unlike albumin, the albumin mRNA level increases at an early stage of liver impairment. 
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Research is needed to confirm this finding, but analysis of levels of circulating nucleic acids 
may be an interesting option for opportune detection of liver damage. Furthermore, in acute 
liver failure, the reduction in the production of albumin and 1-acid-glycoprotein alters the 
protein-bound fraction of many drugs, resulting in higher levels of the free and active forms of 
drugs and their associated effects. Nevertheless, albumin is not entirely specific for liver 
function impairment or injury; therefore, several other biomarkers have been investigated. 
These will be discussed in relation to the various liver pathologies. 
2.1 Alcoholic liver disease 
Although liver disease may have many etiologies, alcohol is still the most frequent cause of 
liver deterioration, whether acute or chronic. The hepatotoxic threshold at which alcoholic 
liver disease (ALD) develops is 40 g of ethanol per day (about four drinks) for men and 20 g of 
ethanol per day (about two drinks) for women and it has been estimated that 7.4% of the adult 
population of the USA and 20–30% of the adult population of Europe consume high quantities 
of alcohol. It is alarming that, in these locations and in many developing countries, the increase 
in alcohol consumption has been continuous and is predicted to continue during the next 
decade. Figure 1 shows worldwide mortality due to alcoholic liver disease. 
 
 
Fig. 1. Annual mortality from alcoholic liver disease. The countries with the highest 
mortality rates are shown. 
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Nevertheless, alcohol consumption is considered by many people to be normal and 
customary; this and the fact that patients usually do not seek medical assistance until the 
damage is well established (it is usually asymptomatic in the early stages) suggests that the 
prevalence of ALD is underestimated. 
Several studies have proven that activation of Kupffer cells increases TNF- secretion, and 
therefore the immune response. Su and colleagues (Su et al., 1998) found in rat models that 
lipopolysaccharide, an endotoxin usually present in Gram-negative bacteria, is responsible 
for the activation of Kupffer cells. Lipopolysaccharide binding protein (LBP) opsonizes cells 
and presents the endotoxin to CD14, a membrane-bound glycoprotein that activates 
macrophages. Alcohol is one of the stimuli necessary to increase the level of LBP-1 and, 
therefore, mediates liver damage. Until recently, IL-17 was thought to play an important 
role in alcohol-induced liver damage by activating T-helper cells, which maintain and 
increase inflammatory damage. 
Another APP that has been associated with alcohol is alpha-fetoprotein (AFP). Although 
AFP has been considered a biomarker for hepatocellular carcinoma (see later in this 
chapter), this can be misleading because AFP is also present in ALD. 
2.2 Liver steatosis 
Nonalcoholic fatty liver disease (NAFLD) is the most common metabolic cause of liver 
dysfunction worldwide. It is believed that 10–24% of the general population has NAFLD, 
most cases of which are asymptomatic. It is a form of chronic liver disease that encompasses 
a wide spectrum of conditions that range from deposits of lipids (liver steatosis) to liver 
damage caused by proinflammatory compounds (nonalcoholic steatohepatitis, NASH). The 
natural history of this pathology has been thoroughly studied and it has been reported that 
NAFLD represents the first step in a progression to NASH (10–20% of cases develop 
NASH), liver cirrhosis (3–5% of cases develop liver cirrhosis), and hepatocellular carcinoma 
(Figure 2). 
 
 
Fig. 2. Natural history of metabolic liver disease. NAFLD, nonalcoholic fatty liver disease; 
NASH, nonalcoholic steatohepatitis. 
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Under normal conditions, the liver is often exposed to endo- and exotoxins, which initiate 
the innate immune response. TNF- target genes are normally expressed at minimal levels, 
preventing damage to the organ. Furthermore, it has been demonstrated that TNF- is 
responsible for promoting liver regeneration. NAFLD and NASH are characterized by an 
increase in free fatty acid levels and NASH is also accompanied by an increase in lipid 
peroxidation and high concentrations of TNF-, which cause mitochondrial dysfunction. 
Mitochondrial impairment renders the cell susceptible to TNF--induced cytotoxic damage. 
Obesity has been considered a major risk factor for the development of NAFLD because it 
produces a proinflammatory state that gradually injures the liver. Nevertheless, authors 
such as Crespo and colleagues found that TNF- levels are significantly higher in patients 
with NASH than in obese patients without NAFLD, suggesting that the former patients 
have increased susceptibility to TNF--mediated injury, rather than there being a cause–
effect relationship between the cytokine and NASH. 
Although several biomarkers of hepatic fibrosis have been identified (as is discussed later in 
this chapter), there are no reliable markers for NAFLD or NASH. Alanine aminotransferase is 
considered a marker for liver injury, but obesity may reduce the level of alanine 
aminotransferase, rendering it misleading in patients with NASH. Another issue is that 
identification of alcoholic and nonalcoholic liver damage is difficult. Gamma-glutamyl 
transpeptidase (GGT) levels are commonly used for this purpose but, in cases of NASH, they 
have also led to uncertain conclusions. Another report (Ohtsuka, 2005) suggested that 
carbohydrate-deficient transferrin could be a marker for differentiating between NAFLD and 
NASH. Nevertheless, Yoneda and colleagues (Yoneda et al., 2008) found that, although CRP 
and amyloid A levels are often used to assess inflammatory injury to the liver in clinical 
practice, these APPs are members of the short pentrexin family, the levels of which are only 
elevated as a systemic response to inflammation, whereas the long pentrexin, PTX3, is rapidly 
induced in damaged tissue in a tissue-specific manner. Thus, they concluded that PTX3 could 
be a more important biomarker for NASH than for non-NASH cases of liver damage. 
2.3 Viral hepatitis 
Infection with the hepatitis C virus (HCV) is a leading cause of chronic liver disease. 
According to the World Health Organization, over 3% of the world’s population (about 180 
million people) is infected and about 130 million are at risk of developing cirrhosis. The 
majority of those infected with HCV (60–80%) develop chronic hepatitis, which is associated 
with progressive fibrosis. Of chronic hepatitis patients, 3–9% develop cirrhosis within 20 years. 
El-Serag and colleagues (El-Serag et al., 2003) found that HCV-infected patients are more 
frequently coinfected with viral or bacterial entities than are patients with other liver 
diseases. Few studies have been performed to explain this finding, but Wegert and 
colleagues (Wegert, 2009) found that CRP, SAA, haptoglobin, and fibrinogen levels are 
diminished secondary to an impairment caused by an HCV core protein that inhibits 
activation of transcription factors for protein production and disrupts TNF- and IL-6 
signaling, affecting the whole immune response, at least in mice. Complement activity has 
also been suggested as an inducer of fibrosis and, therefore, of progression to cirrhosis in 
HCV-infected patients. It was reported that C5 is associated with this progression 
(Hillebrandt, 2005), but subsequent studies have failed to demonstrate this relationship; 
thus, it is unclear if this component is relevant to the induction of fibrosis in humans 
(Halangk, 2008). Despite this, the involvement of complement in the progression of fibrosis 
is still a topic of research. Interestingly, HCV-infected patients also have significantly lower 
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cholesterol levels than normal subjects. This may be associated with APP level, which, as 
mentioned before, is reduced, as in the proinflammatory and proatherogenic states. 
On the other hand, even though vaccination has considerably diminished the number of cases 
of HBV infection, the prevalence of this disease is high. About 350 million people worldwide 
are infected and are at risk of progression to a worse state (Te, 2002). Some authors have found 
that the response to the vaccine is closely related to complement activity. C4, a crucial protein 
for the classical complement pathway, links innate immunity with adaptive immunity by 
targeting the antigen to follicular dendritic cells and B cells through the specific receptors, 
CD21 and CD35. It has been shown that patients who do not show the expected response to 
the vaccine have human leukocyte antigen class-II alleles, which impair C4 activity. Vaccines 
should be linked to complement fragments to avoid this problem. 
Both HCV and HBV infections are considered chronic. This characteristic enables a 
proinflammatory state to exist, which will eventually affect the synthesis of APP in the liver. 
Although other hepatotropic infections may also produce an acute state, it is usually self-
limited and therefore the levels of APP do not change markedly. 
2.4 Liver cirrhosis 
Fibrosis is a type of tissue repair that is characterized by the replacement of normal 
parenchyma with connective tissue (collagen) and is mainly secondary to chronic 
inflammation. Fibroblasts and myofibroblasts are partly responsible for this process, and it 
is important to note that the principal stimulus for these cells is IL-6, which is initially 
secreted by macrophages and subsequently secreted by B cells at the site of the lesion. When 
inflammation is chronic, the stimulus is persistent; thus, abundant amounts of collagen are 
synthesized, resulting in abnormal accumulation of connective tissue. The gold standard for 
the diagnosis of cirrhosis is still the liver biopsy. Several scoring systems have been 
developed to stage cirrhosis. The Metavir scoring scale is most commonly used to indicate 
the grade of inflammation and scarring on the liver and was first developed for HCV-
infected patients. The Knodell score is a histological staging system that assesses the extent 
of inflammation: a score of 0–10 is allocated to periportal or bridging necrosis and a score of 
0–4 is allocated to intralobular degeneration and portal inflammation. The various grades 
used in these two scoring systems are shown in tables 2 and 3. 
 
Grade Description
0 No scarring
1 Minimal scarring
2 Scarring has occurred and extends to blood vessels
3 Bridging fibrosis
4 Advanced scarring, cirrhosis
Table 2. The METAVIR scoring system for cirrhosis. 
 
Score Description
0 No inflammation
1–4 Minimal inflammation
5–8 Mild inflammation
9–12 Moderate inflammation
13–18 Marked inflammation
Table 3. The Knodell scoring system for cirrhosis. 
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Although the gold standard for the diagnosis of cirrhosis is the liver biopsy, the invasive 
nature of this procedure makes it difficult to perform with every patient. Although 
noninvasive methods such as the FibroScan and FibroTest are available, they may result in 
false-negative results in obese patients or patients with ascites. Although CRP and serum 
amyloid A (SAA) levels are biomarkers for liver injury and inflammation, it has been 
demonstrated that they are not correlated with fibrosis. Fortunately, there are other 
biomarkers that have been validated in several studies. Alpha-2 macroglobulin (A2M) is a 
protein that inactivates proteinases and inhibits fibrinolysis by reducing plasmin and 
kallikrein expression; thus, it inhibits the catabolism of matrix proteins, facilitating the 
development of fibrosis. The FibroTest involves this biomarker (Franciscus, 2010). The level 
of apolipoprotein A1 (ApoA1), a structural component of high-density lipoprotein 
cholesterol, is also correlated with the advanced stages of fibrosis (F3–F4). Other authors 
(Ho et al., 2010) described a novel biomarker: vitamin D binding protein (VDBP). Although 
A2M expression is upregulated in fibrotic livers, both ApoA1 and VDBP are negative APPs 
and are downregulated in fibrotic livers. 
As mentioned in the introduction, there are several signaling pathways that control diverse 
functions. In the case of fibrosis, the STAT 3 family has the greatest impact. Activation and 
high activity of this signaling pathway have been implicated in the genesis of cirrhosis as 
well as in its evolution to HCC. Under normal circumstances, insulin-like growth factor-1 
(IGF-1) maintains the activity of the STAT 5 signaling pathway; nevertheless, when liver 
damage occurs, growth hormone is released, with consequent lowering of IGF-1 level 
(therefore, it is known as a negative APP), which stops the activation of the STAT 5 pathway 
and the phosphorylation of STAT 3. TGF- is a closely related cytokine because it is also 
secreted when liver damage occurs and it activates the STAT 3 pathway as well as the 
expansion of T-helper cells, which increases fibrosis. 
It has also been reported (Parsian et al., 2010) that expression of other components such as 
hyaluronic acid, alpha glycosaminoglycan distributed in extracellular spaces and 
synthesized by hepatic stellate cells in the liver, and laminin, a basal membrane glycoprotein 
synthesized in hepatocytes, also increase in the early stages of fibrosis in chronic liver 
diseases. These serum parameters have been compared with APP-based indices such as A1-
apolipoprotein level and prothrombin time, and it was found that hyaluronic acid is the 
most strongly correlated with liver fibrosis. 
2.5 Hepatocellular carcinoma and other liver tumors 
As mentioned in the discussion of cirrhosis, downregulation of the STAT 5 signaling 
pathway and activation of the STAT 3 pathway increase fibrosis. Practically all chronic liver 
diseases result in fibrosis and, if not controlled, in malignant transformation of hepatocytes, 
and HCC (figure 3). 
HCC accounts for 5.6% of all human cancers, more so among men than women (7.5% and 
3.5%, respectively), and its prevalence increases with age. It has a 5-year survival rate of 
6.5% and is considered responsible for 660,000 deaths per year worldwide. Viral hepatitis, 
alcohol, oral contraceptives, and aflatoxins are the most important risk factors for its 
development and its prevalence is expected to increase in the future. 
HCV and HBV infection are the main causes of HCC; they are responsible for 80% of HCC 
cases (96% in HBV endemic regions). It has been established that 10–40% of all chronic HBV 
patients will develop this entity. The progression to liver cancer is monitored using serum 
levels of alpha-fetoprotein (AFP), an oncofetal glycoprotein that serves as an APP for several  
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Fig. 3. Evolution and risk factors for the development of hepatocellular carcinoma. 
liver diseases; nevertheless, it is not cancer specific. Comunale and colleagues (Comunale et 
al., 2010) identified more than 100 glycoproteins that are elevated in cirrhotic and HCC 
patients and that may serve as markers of the early development of HCC, and they 
suggested that alpha-1-antitrypsin was the most promising. 
CRP and SAA levels are correlated with tumor activity (Jong, 2001), i.e., with increasing tumor 
load, necrotic tumors, and tissue destruction. Levels of these proteins are even increased by 
gastric and colorectal metastases. It has also been suggested that APPs provide an ideal 
environment for tumor recurrence or growth (Harimoto et al., 2009). It is also accepted that 
CRP-positivity in HCC patients often indicates a poor prognosis and portal vein invasion. 
As mentioned earlier in the chapter, hypoalbuminemia was considered a marker of liver 
impairment. For a long time, it was thought that tumor activity was responsible for the 
decrease in albumin level; however, recent studies (Al-Shaiba et al., 2004) have 
demonstrated that the reduction in serum albumin level is related to the inflammatory 
response rather than to nutritional depletion caused by the tumor. 
2.6 Autoimmune hepatitis 
Autoimmunity is also an important cause of liver disease. It encompasses a broad spectrum 
of diseases, including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary 
sclerosing cholangitis (PSC), and autoimmune cholangitis. The most common are AIH and 
PBC. Clinical, biochemical, histopathological, and cholangiographic criteria are used for 
differential diagnosis (Table 4). 
AIH is characterized by severe liver damage with a modest or low elevation of alkaline 
phosphatase level (Oo,  2010). It is classed into three types according to the autoantibodies 
expressed: type 1, smooth muscle antibodies (SMA) or anti-nuclear antibodies (ANA) are 
present; type 2, anti-liver kidney microsomal antibodies (LKM) are present; and type 3, 
soluble liver antibodies (SLA) or liver/pancreas antigens are present. All of these antibodies 
induce proinflammatory cells that mostly activate T-helper cells, which cause liver damage. 
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Parameter AIH PBC PSC AIC 
Female:male 4:1 9:1 1:2 9:1 
Liver test 
elevation 
ALT, AST AP, GGT AP, GGT AP, GGT 
Ig elevation IgG IgM IgG, IgM IgM 
Autoantibodies ANA, ASMA, 
LKM, SLA, p-
ANCA 
AMA, AMA-M2 p-ANCA ANA, ASMA 
HLA association A3, B8, DR3, DR4 DR8 DR52 B8, DR3, DR4 
Histology Lymphocyte 
interface hepatitis
Florid bile duct 
lesion 
Fibrosing bile 
duct lesion 
Florid bile duct 
lesion 
Table 4. Comparative table for the differential diagnosis of autoimmune liver diseases. AIH, 
autoimmune hepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; 
AIC, autoimmune cholangitis; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; AP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; Ig, 
immunoglobin; ANA, anti-nuclear antibodies; ASMA, anti-smooth muscle antibodies; LKM, 
anti-liver kidney microsomal; SLA, anti-soluble liver antigen; p-ANCA, perinuclear anti-
neutrophil cytoplasmic antibodies; AMA, anti-mitochondrial antibodies; UDCA, 
ursodeoxycholic acid. 
In PBC (Poupon, 2010), inflammation is associated with similar rates of apoptosis and 
proliferation of biliary cells. Cytolytic T cells are attracted to autoantibody-marked cells by 
cytokines and chemokines, which also induce the killing of cells via TNF-, CD-40, and Fas 
receptors. It is under this pressure that cholangiocytes proliferate to compensate for cell 
death. It has been suggested that the cholinergic pathway, the IGF-1 system, and estrogens 
(through alpha receptors) are possible mediators of this process. 
Takahashi and colleagues (Takahasi et al., 2010) found that ALT and transferrin levels are 
correlated in autoimmune diseases and in other collagen-related diseases. CRP and AP 
levels are also correlated, at least in vasculitis syndrome. The explanation for these results is 
that, because the immunological response is increased in all these diseases, APPs are 
induced. IL-17 is a new cytokine that has been suggested to play an important role in the 
pathogenesis of AIH, as it is a strong neutrophil recruiter and, importantly, is also 
associated with the pathogenesis of ALD. 
Furthermore, several authors have described “overlap syndromes”. These entities are 
characterized by clinical or biochemical features common to two or more autoimmune 
diseases affecting the liver. In overlap syndromes, the magnitude of the immunological 
response in the early stage is elevated in that APP levels are altered to a greater extent. 
Comorbidities are not considered overlap syndromes. Kessel and colleagues (Kessel et al., 
2007) reported that HCV-infected patients have a high titer of CRP antibodies, which is 
correlated with the level of rheumatoid factor, cryoglobulinemia, and the severity of liver 
disease, suggesting that it facilitates autoimmune liver disorders. This is important because 
it has been shown that 65% of patients infected with HCV have low titers of ANA, SMA, 
and anti-thyroid antibodies, and 7% have anti-LKM-1 antibodies. Some authors suggest 
that, if titers of these antibodies are >1:320, and/or hypergammaglobulinemia, and other 
risk factors (female gender, young age, and other autoimmune disorders) are present, it 
should be considered as a co-morbidity between HCV and AIH (Beuers, 2005). 
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3. Clinical repercussions 
Clinically, insulin resistance (IR) and cardiovascular disease (CVD) have been suggested to 
arise from a common basis, i.e., chronic inflammation. As mentioned before, chronic liver 
diseases are important sources of a proinflammatory state and, therefore, several studies 
have tried to link liver impairment with the development of IR, type 2 diabetes mellitus 
(T2DM), and CVD. It is important to comment on this situation because several reports have 
suggested that the prevalence of chronic liver diseases will increase in the next few years 
and have shown that chronic liver diseases are currently among the leading causes of 
mortality in all parts of the world. 
3.1 Liver-related insulin resistance (IR) 
One of the manifestations of liver impairment is IR. IR is defined as an increased need for 
insulin in the peripheral tissues (muscle and adipose tissue) to achieve normal cellular 
glucose uptake and to reduce glucose output from the liver. The incidence of T2DM is 
increasing worldwide. IR is considered the pathophysiological basis of T2DM and is 
responsible for micro- and macrovascular complications associated with this condition. 
Some studies have associated IR with other deleterious effects on the biliary tract and liver 
such as the induction of gallstones and NAFLD, considered the most common chronic liver 
disease in Western countries and the liver manifestation of metabolic syndrome (MS), a 
pathology proven to be intrinsically related to IR. Some studies have even found that IR 
tends to favor the progression of NAFLD to NASH, cirrhosis, and HCC. 
To comprehend the entire pathophysiology of IR, it is important to understand the normal 
physiology of insulin signaling. The main signaling pathway begins with the binding of 
insulin to its receptor, which activates insulin receptor substrates (ISR-1 or ISR-2), which 
activate phosphatidylinositol-3 kinase (PI3K). The subsequent cascade results in the 
production of protein kinase Corwhich promotes translocation of the glucose 
transporter, GLUT 4, and activation of Akt, facilitating glucose uptake, gluconeogenesis, 
and protein synthesis through the production of GSK-3, FOXO-1, and mTOR, respectively. 
The last-mentioned mediator also exerts negative feedback on insulin signaling by 
phosphorylating IRS-1 (Méndez et al., 2005) (figure 4). 
Two main pathways are involved in liver-related IR. One path is through the production of 
free fatty acids, an increased level of which inhibits insulin-induced suppression of 
endogenous glucose production, and the other is through stimulation of gluconeogenesis, 
associated with activation of protein kinase C. 
Nevertheless, there are other factors associated with IR, such as a mutation of 2,6 fructose 
bisphosphonatase that causes an alteration in the fructose 2,6-bisphosphonate, which causes 
three results: a lower efficiency of suppression of hepatic glucose production (increased 
gluconeogenesis); a disruption of glucose flux, and a decrease in insulin-induced Akt 
phosphorylation in the liver. Furthermore, phosphorylation of ISR-2 in the cascade of 
activation of insulin also has an important impact on glycogen synthesis. It has been 
demonstrated that ISR-2 phosphorylation inhibits glycogen synthetase-3-kinase, which, in 
normal situations, induces glycogen synthesis and increases the use of plasma glucose. In 
pathological cases, synthesis is interrupted and glucose is not taken up by cells, promoting 
the progression of IR. 
www.intechopen.com
 The Role of the Acute-Phase Proteins in the Development and Progression of Liver Diseases 
 
117 
 
Fig. 4. Mechanisms involved in insulin signaling. Under normal circumstances, insulin 
binds to its receptor, which activates IRS 1/2, which then initiates a cascade of reactions that 
activate PKC, inducing the synthesis and migration of GLUT4 to the cell membrane, and 
Akt, which promotes glucose uptake, gluconeogenesis, and protein synthesis. mTOR also 
exerts negative feedback on the activation of IRS. IRS, insulin receptor substrate; PI3K, 
phosphatidylinositol-3 kinase; PKC, protein kinase C. 
 
 
Fig. 5. Liver-related insulin resistance. FFA, free fatty acids; IRS, insulin receptor substrate. 
As mentioned before, TNF- concentrations are elevated in liver diseases and, through the 
activation of inhibitory , which enables activation of nuclear factor-, cause 
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upregulation of IL-6. IL-6 induces the suppressor of cytokine signaling (SOCS), which 
induces IR through a specific inhibitor of IRS-2 (SOCS-1) or by competition for the docking 
sites of SOCS-3 (Méndez et al., 2005). 
Festa and colleagues (Festa et al., 2002) reported that APPs are not only impaired in cases of 
T2DM but proposed that they serve as early biomarkers of T2DM. CRP and fibrinogen were 
related to IR, but several studies have related them to adipose tissue secretion, and therefore 
to body mass index. Nevertheless, they also found that PAI-1 was independently related to 
the development of T2DM when compared with BMI and other risk factors, even IR, 
suggesting that this APP is suitable for early screening of people who are predisposed to 
T2DM. 
Recent studies have also confirmed a close relationship between IR and liver diseases such 
as chronic hepatitis caused by HBV and HCV, hemochromatosis, cirrhosis, and HCC. Some 
authors have even reported so-called “hepatogenous diabetes”, which is recognized by the 
World Health Organization as an independent entity that refers to the development of the 
T2DM due to cirrhosis. 
It is important to note that the incidence of viral hepatitis has increased worldwide, 
especially the types that produce a chronic state. In regards to these, some studies have 
reported that HCV infection induces degradation of IRS-1 through activation of the mTOR 
pathway (genotype 1) or SOCS-7 and PPAR- (genotype 3). In either eventuality, the result 
is IR. It is also important to mention that these two genotypes have been related to IR in 
HCV infection. 
Several studies have been performed to analyze the relationships of IR and T2DM with liver 
disease. Although the prevalence of liver diseases varies between countries, it has been 
noted that liver cirrhosis and viral hepatitis C infection have the strongest relationship with 
T2DM; nevertheless, other liver diseases have also been correlated with T2DM. Table 5 
shows the prevalence of these diseases. 
3.2 Relationship between cardiovascular risk and liver impairment 
Metabolic syndrome is the pandemic of the new millennium and is considered a major risk 
factor for CVD. NAFLD is now considered a liver manifestation of this syndrome. As 
mentioned before, IR is the pathophysiological basis of metabolic syndrome and is therefore 
closely linked to both CVD and liver diseases. 
As also mentioned above, CRP is considered the most important APP correlated with IR and 
CVD; nevertheless, there are some studies that have shown that CRP has anti-inflammatory 
properties and is involved in the reduction of the development of atherosclerosis in mouse 
models with hypercholesterolemia. This is most probably due to CRP-mediated 
upregulation of the IL-1 receptor antagonist and upregulation of serum leptin-interacting 
protein activity. 
NASH, as also mentioned before, characteristically elevates CRP, PAI-1, and fibrinogen 
activities (more so than NAFLD), which are also correlated with CVD and could be 
considered markers for this entity because these APPs have been demonstrated to be related 
to cardiovascular events independently of other risk factors such as age, visceral adiposity, 
and metabolic abnormalities. As such, patients with viral hepatitis also have a markedly 
greater carotid artery intimae medial thickness. Figure 6 shows the physiopathology of this 
interaction. 
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 Study Country Prevalence of T2DM (%) 
Hepatitis B virus 
Arao M et al., 2003 Japan 11.9
Knobler H et al., 2000 USA 12
Kobashi R et al., 2010 Mexico 16.7
Hepatitis C virus
Moucari R et al., 2008 USA 33
Mangia A et al., 1998 Italy
23 
Lecube A et al., 2004 Spain
Arao M et al., 2003 Japan 20
Singal AK et al., 2008 Saudi Arabia 22
Fraser GM et al., 1996 Israel 39
Kobashi R et al., 2010 Mexico 22.7
Nonalcoholic fatty liver disease
Dixon JB et al., 2001 USA 20–45
Gaiani S et al., 2009
Italy 
80
Bellentani S et al., 2007
30–50 
Targher G et al., 2007
Mendez N et al., 2007 Mexico 15.9–45 
DeLusong MAA et al., 2008 Philippines 60
Kobashi R et al., 2010 Mexico 17.6
Nonalcoholic steatohepatitis
Nugent C et al., 2007
USA 25–45 
Harrison SA et al., 2006
Prashanth M et al., 2009
India 
25
Amarapurkar DN et al., 2008 27
Kobashi R et al., 2010 Mexico 25
Cirrhosis 
Tolman KG et al., 2007
USA 
25–30 
Hickman IJ et al., 2007
Zeinn NN et al., 2000 34
Arao M et al., 2003 Japan 30.8
Costa-Braganca et al., 2010 Brazil 64.5
Kobashi R et al., 2010 Mexico 34.4
Hepatocellular carcinoma
Davila JA et al., 2010 USA 9.7
Donadon V et al., 2008 Italy 31.2
Lagiou P et al., 2000 Greece 18
Kobashi R et al., 2010 Mexico 35.7
Hemochromatosis
Sampson MJ et al., 2000
USA 
0.4
Conte D et al., 1998 1.34
Adams PC et al., 1991 50–85 (hereditary) 
Kobashi R et al., 2010 Mexico 0.77 (general) 
Autoimmune hepatitis
Jalihal A et al., 2009 Brunei 21
Choudohuri G et al., 2003 India 39.5
Kobashi R et al., 2010 Mexico 25
Table 5. Prevalence of type 2 diabetes mellitus (T2DM) and liver diseases reported from 
several studies worldwide (from Kobashi et al., 2010). 
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Fig. 6. Relationship between liver steatosis and cardiovascular events (atherosclerosis). 
Several APPs are elevated in NASH, which may directly injure the endothelium, but 
adipose tissue alone may also produce the same alteration. FFA, free fatty acids; IR, insulin 
resistance; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; 
TG, triglyceride; VLDL, very low density lipoprotein; HDL, high density lipoprotein. 
It is important to mention that several risk factors for the development of CVD are also 
important risk factors for diabetes and some liver diseases. The transport of cholesterol is 
intrinsically related to these pathologies. Recently, studies have focused on the ATP binding 
cassette, A-1 (ABCA-1), an ATP-binding membrane transporter that plays an important role 
in cholesterol efflux from tissues and interacts directly with apolipoprotein A1, which is a 
structural component of high density lipoprotein cholesterol (HDL-c) and therefore plays a 
crucial role in lipid transportation. Because ABCA-1 and Apo-A1 have been demonstrated 
to be reduced in some liver diseases, it is comprehensible that liver impairment could be 
reflected in decreased HDL-c levels through this mechanism (Figure 7). HDL-c plays a 
protective role in cardiovascular events because it transports cholesterol from peripheral 
tissues to the liver where lipid is metabolized. The metabolism and transport of cholesterol 
demonstrates the close relationship between liver diseases and cardiovascular events. 
Several studies have also pointed out that adiponectin, an adipocyte-derived enzyme, plays 
a protective role in the pathogenesis of liver impairment (induction of NAFLD) and 
therefore, in the increase in cardiovascular risk. Acetyl-CoA carboxylase (ACC) and fatty 
acid synthase (FAS) are important rate-limiting enzymes for fatty acid synthesis. The  
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Fig. 7. Cholesterol reverse transport metabolism. Oxysterols (ligands for LXR receptors) and 
activators of PPAR induce the production of ABC-A1, which transports molecules of 
cholesterol from inside the cell to the outer cell membrane. Once presented, the structural 
molecule, ApoA1, of HDL-c attaches to the molecules of cholesterol and they are 
transported to the liver where they can be metabolized and excreted from the organism. In 
the absence of HDL-c stimulation (i.e., in liver diseases), the LXR- receptor and RXR are 
activated and inhibit ABC-A1, maintaining cholesterol accumulation within tissues. LXR, 
liver X receptor; RXR, retinoid X receptor. 
activity of these enzymes and that of carnitine palmitoyl transferase I (CPT-I), which 
mediates fatty acid entry to the mitochondrion, where the fatty acids are degraded, are 
regulated by adiponectin. This enzyme promotes CPT-I expression and inhibits ACC and 
FAS expression, reducing serum and hepatic lipid concentrations and, thus, the activity of 
TNF-. Uribe and colleagues (Uribe et al., 2008) have shown that adiponectin expression is 
reduced in metabolic liver diseases and in obesity. 
4. Conclusions  
Although albumin level is generally correlated with liver disease, it is not specific for the 
various liver diseases. Consequently, several studies have been conducted to identify 
biomarkers specific for each liver disease. Table 6 lists APPs associated with various liver 
diseases. 
It is important to mention that although chemical analysis has improved over the years, the 
clinical status of the patient is the most important and reliable factor in the approach of the 
patient. APPs measurement gives the clinician, the proper guidance and orientation of the 
problems, that usually are subclinical, but they are not the gold standard for any liver 
disease; therefore, they all need a confirmation with some other studies.  
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Liver disease Positive APP Negative APP 
Alcoholic disease AFP, LBP-1  
NAFLD ALT  
NASH GGT, CRP, SAA, PTX3  
Viral hepatitis  CRP, SAA, Fibrinogen, 
Complement activity (C4, C5) 
Cirrhosis A2MG ApoA1, VDBP, HA, IGF-1 
HCC AFP, A1AT, CRP, SAA  
Autoimmune CRP, ALT, AP  
Table 6. APP, acute-phase protein; AFP, alpha-fetoprotein; LBP-1, lipopolysaccharide 
binding protein 1; NAFLD, nonalcoholic fatty liver disease; ALT, alanine aminotransferase; 
NASH, nonalcoholic steatohepatitis; GGT, gamma-glutamyl transpeptidase; CRP, c-reactive 
protein; SAA, serum amyloid A; PTX3, pentrexin 3; A2MG, alpha-2 macroglobulin; ApoA1, 
apolipoprotein A1; VDBP, vitamin D binding protein; HA, hyaluronic acid; IGF-1, insulin-
like growth factor-1; HCC, hepatocellular carcinoma; A1AT, alpha-1 antitrypsin; AP, 
alkaline phosphatase. 
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